Todos os estudos
Ativo, mas não recrutandoFASE2INTERVENCIONISTA

A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)

This study is looking at a new way to treat certain advanced skin lymphomas (Cutaneous T-cell Lymphoma including Mycosis Fungoides and Sezary Syndrome) that have come back or haven't gotten better with other treatments. It combines a drug called pembrolizumab, which helps your immune system fight cancer, with radiotherapy, a type of radiation treatment. Patients will receive pembrolizumab as a drip every three weeks, and then radiotherapy will be added around week 12. The aim is to see if this combination works safely and effectively. Participants will be monitored closely for up to two years after starting treatment.

Em resumo

Status
Ativo, mas não recrutando
Fase
FASE2
Patrocinador
University College, Londres
Meta de inscrição
46
Iniciar
15 de jan de 2019
Conclusão estimada
01 Sep 2025

Sobre o que é este estudo?

This research study is about finding better treatments for a type of skin cancer called Cutaneous T-cell Lymphoma (CTCL). Specifically, it focuses on two forms of CTCL: Mycosis Fungoides (MF) and Sezary Syndrome (SS). These conditions affect your skin and, for people in this study, have either come back or not responded well to other treatments they've had in the past. The study is investigating a new combination of treatments, hoping to improve outcomes for patients.

The main treatments being tested are pembrolizumab and radiotherapy. Pembrolizumab is a modern type of cancer drug known as an immunotherapy. It works by boosting your body's own immune system to recognise and fight cancer cells. Radiotherapy uses targeted radiation to kill cancer cells and shrink tumours in specific areas. Researchers believe that using these two treatments together might be more effective than using either one alone.

The study wants to see how well this combined approach works and if it's safe for patients. By carefully monitoring participants, the researchers hope to gather important information that could lead to new ways of treating these challenging skin lymphomas for many more people in the future.

Pontos principais

  • This study combines two treatments: pembrolizumab (immunotherapy) and radiotherapy.
  • It's for people with specific advanced skin lymphomas (Mycosis Fungoides/Sezary Syndrome) that haven't responded to previous treatments.
  • Pembrolizumab is given every three weeks; radiotherapy starts around week 12.
  • The study aims to see if this combination is safe and effective.
  • Participation involves regular hospital visits and follow-up for up to two years.
  • Você pode parar de participar a qualquer momento.

Quem pode ser elegível?

To join this study, you need to be at least 18 years old and have a specific type or stage of skin lymphoma called Mycosis Fungoides (MF) or Sezary Syndrome (SS). Your lymphoma should have either returned, not responded to, or progressed after at least one other whole-body treatment. You'll need to have had a recent skin test (biopsy) and have some areas of skin affected by the lymphoma that can be measured and one area that can be treated with radiotherapy.

There are also some general health requirements, including having a good level of physical activity, a life expectancy of at least six months, and healthy organ function. You shouldn't have had certain other cancer treatments or medicines recently. If you are female and could become pregnant, you'll need to have a negative pregnancy test and agree to use contraception during the study. Everyone must be willing to provide their informed consent to participate.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Você tem 18 anos ou mais?
  2. Do you have Mycosis Fungoides or Sezary Syndrome that has returned or not responded to previous treatments?
  3. Do you have areas of skin affected by lymphoma that can be measured and treated with radiotherapy?
  4. Are you generally well enough to walk and carry out light activities?
  5. Have you discussed recent treatments with your doctor?
  6. If you could become pregnant, are you willing to use contraception during the study?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you decide to join this study, you will receive pembrolizumab, an immunotherapy drug, through a drip into your arm every three weeks. Around week 12, you will also start special X-ray treatment called radiotherapy, which will be given in three short sessions, still alongside your pembrolizumab. If your condition gets worse before week 12, you might start radiotherapy sooner. After finishing radiotherapy, you will continue with pembrolizumab every three weeks for up to two years, unless your condition gets worse or you experience side effects that are too much to handle.

Throughout the study, you will have regular check-ups, usually every three weeks, for up to two years to see how you are doing and check for any side effects. If you stop taking pembrolizumab, you will have annual check-ups to monitor your health. The total time you will be involved in follow-up appointments could be several years until the study officially ends.

Riscos e benefícios potenciais

Participating in a clinical trial may offer potential benefits, such as access to new treatments before they are widely available, and your health will be closely monitored by a dedicated medical team. However, there are also potential risks involved. The treatments, pembrolizumab and radiotherapy, can cause side effects, some of which may be serious. You will be told about all known side effects before you decide to join. It's important to remember that the new treatment might not work for everyone. You have the right to withdraw from the study at any time, for any reason, without affecting your usual medical care.

Localizações (11)

  • University Hospital Birmingham
    Código postal verificado
    Birmingham, Reino Unido
  • Velindre Cancer Centre
    Código postal verificado
    Cardiff, United Kingdom
  • University Hospital Coventry
    Código postal verificado
    Coventry, United Kingdom
  • Beatson West of Scotland Cancer Centre
    Código postal verificado
    Glasgow, Reino Unido
  • Guy's & St Thomas'
    Código postal verificado
    Londres, Reino Unido
  • The Christie
    Código postal verificado
    Manchester, Reino Unido
  • Clatterbridge Cancer Centre
    Código postal verificado
    Metropolitan Borough of Wirral, United Kingdom
  • Freeman Hospital
    Código postal verificado
    Newcastle, United Kingdom
  • Nottingham City Hospital
    Código postal verificado
    Nottingham, Reino Unido
  • Churchill Hospital
    Código postal verificado
    Oxford, Reino Unido
  • Southampton University Hospital
    Código postal verificado
    Southampton, Reino Unido

Perguntas frequentes

What is Cutaneous T-cell Lymphoma (CTCL)?

CTCL is a rare type of cancer that starts in white blood cells called T-cells and primarily affects the skin, causing rashes, patches, or tumours.

What is pembrolizumab?

Pembrolizumab is an immunotherapy drug that helps your body's immune system find and fight cancer cells.

What is radiotherapy?

Radiotherapy uses high-energy rays to kill cancer cells and shrink tumours in a specific area of the body.

How often will I need to visit the hospital?

You'll have a main treatment every three weeks, plus additional visits for radiotherapy and regular check-ups, for up to two years.

Can I stop participating in the study early?

Yes, you have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Como saber mais

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.